News


AICUBE signs an exclusive license agreement with the Istituto Italiano di Tecnologia concerning the Italian patent no. IT001403160 and European patent no. EP 2648866 on the invention entitled

"Procedure for the synthesis of stellate gold nanoparticles with controlled dimensions and branching and stellate gold nanoparticles thus obtained"

(MAIORANO, GABRIELE; RIZZELLO, LORIS; SANGARU, SHIV SHANKAR; CINGOLANI, ROBERTO; POMPA, PIER PAOLO)

AICUBE and IIT are strategic partners in the development of DOC.D©, an innovative non-invasive device for measuring salivary glucose.

Milan 8 November 2021 - Milan-based innovative startup AICUBE, strongly oriented towards proactive prevention and predictive medicine through Machine Learning algorithms, has signed a contract with researchers from the "Nanobiointeractions and Nanodiagnostics" team of the Italian Institute of Technology (IIT), led by Pierpaolo Pompa, which operates at the Institute's headquarters in Genoa, the largest research infrastructure in the entire IIT network and where the Foundation started its activities in 2006.

In 2021 AICUBE achieved important goals in research, device development and capital raising. It has therefore started the industrialization process that will lead it to the next stage of industrial prototyping. The relationship with IIT continues with mutual satisfaction in the development and industrialization of the colorimetric sensor for the measurement of salivary glucose whose technology is the basis of our device.

The Italian Institute of Technology (IIT) is a state-funded scientific research centre that promotes technological development with the aim of supporting excellence in basic and applied research to foster the development of the national economic system. IIT's research activity is characterized by a strong multidisciplinary approach and covers four scientific areas: robotics, computational science, life science technologies and nanomaterials.

The DOC.D© device development project involves several phases and the entry of new industrial partners to achieve our goal of increasing the level of secondary prevention. There is in fact the possibility of making an early diagnosis of diseases which, if diagnosed in time, can be cured or their associated complications reduced.

Secondary prevention can be implemented by collecting the values of specific biomarkers on a daily or weekly basis to obtain statistically significant data.

We have therefore patented a device that non-invasively measures salivary glucose in type II diabetic patients on a daily basis in order to characterise its trend. The aim of this important collaboration is to industrialise the sensor that measures changes in this important parameter.



AICUBE signs an agreement with Datamantix for the feasibility study and prototyping of Artificial Intelligence in the characterization of vibrations in Parkinson's patients.

AICUBE and Datamantix are strategic partners for the development of DOC.D©, an innovative non-invasive device that aims to characterize the vibrations of Parkinson's patients using Data Science and Machine Learning techniques.

Milan 5 October 2021 - AICUBE innovative startup, based in Milan, strongly oriented towards proactive prevention and predictive medicine through Machine Learning algorithms, has signed a contract with Datamantix innovative startup, based in Udine, Italy, which deals with the design and development of advanced Artificial Intelligence systems.

In 2021, AICUBE achieved important goals in research, device development and capital raising. It has therefore begun the industrialization process that will take it to the next stage of industrial prototyping. The relationship with Datamantix is the result of an intense period of evaluation of various companies in the field of industrial design with the aim of finding the best partner for this important phase of the company.

Datamantix S.r.l., founded by PhDs in Computer Science with international experience in Artificial Intelligence and Software Engineering, develops advanced technological systems to enable its customers to exploit the potential of their data, knowledge, and skills.

The DOC.D© device development project involves several phases and the entry of new industrial partners to achieve our goal of increasing the level of secondary prevention. In fact, there is the possibility of making an early diagnosis of diseases which, if diagnosed in time, can be cured or their associated complications reduced.

Secondary prevention can be implemented by collecting the values of specific biomarkers on a daily or weekly basis to obtain statistically significant data.

We have therefore patented a "smart" toothbrush that non-invasively measures tremor in parkinsonian patients on a daily basis in order to characterize its progress. The aim of this important collaboration is to find the Machine Learning algorithm that best determines the variations of this important evaluation parameter.


AICUBE signs an agreement with Bartels Mikrotechnik for the development of the microfluidic system.


AICUBE and Bartels Mikrotechnik strategic partners for the development of DOC.D©, an innovative non-invasive device for measuring salivary glucose in type II diabetic patients.

Milan 31 March 2021 - AICUBE innovative startup, based in Milan, strongly oriented to proactive prevention and predictive medicine through Machine Learning algorithms, has signed a contract with Bartels Mikrotechnik medical engineering company in the development of a microfluidics solution of the AICUBE project.

In 2020, AICUBE achieved important goals in research, device development and capital raising. It has therefore begun the industrialization process that will take it to the next stage of industrial prototyping. The relationship with Bartels Mikrotechnik rises from an intense period of evaluation of various companies, universities and research centers in the field of microfluidics with the aim of finding the best partner for this important phase of the company. Bartels Mikrotechnik is the third company, after PQ Design Group and ATLAS Advanced Technologies, with which AICUBE decides to collaborate on the DOC.D© project.

Bartels Mikrotechnik is a globally active manufacturer and development service provider in the field of microfluidics. In the microEngineering division, the company supports industrial customers in the modification, adaptation and new development of high-performance and market-oriented product solutions through the innovative means of microsystems technology. The second division, microComponents, produces and distributes microfluidic products and systems, especially for miniaturized and portable applications. Our key products are micropumps that convey smallest quantities of gases or liquids and are used in a variety of ways in biotechnology, pharmaceuticals, medical technology and numerous other applications.

The development project of the DOC.D© device foresees different phases and the joining of new industrial partners in order to achieve our goal, that of increasing the level of secondary prevention. There is in fact the possibility to make early diagnosis of diseases that if diagnosed in time can be cured or at least reduce the associated complications.

Secondary prevention can be implemented by collecting the values of specific biomarkers on a daily or weekly basis in order to have statistically significant data.

Therefore, we have patented a device that non-invasively collects a saliva sample using an "augmented" electric toothbrush. The saliva sample is then moved to a unit (base) that measures the value of the reference biomarker such as glucose for diabetes or covid- like tests in the future (once clinically tested).

AICUBE signs an agreement with ATLAS - Advanced Technologies for industrial engineering.

AICUBE and ATLAS Advanced Technologies are strategic partners in the development of DOC.D©, an innovative non-invasive device for the measurement of salivary glucose in type II diabetic patients.

Milan February 16, 2021 - AICUBE innovative startup, based in Milan, strongly oriented to proactive prevention and predictive medicine through Machine Learning algorithms, has signed a contract with ATLAS Advanced Technologies consulting company in the development of an IoT solution for the HW-FW-SW architecture of the AICUBE project.

In 2020, AICUBE achieved important goals in research, device development and capital raising. It has therefore started the industrialization path that will lead it to the next phase of industrial prototyping. The relationship with ATLAS Advanced Technologies comes from an intense period of evaluation of different companies in the field of applied electronics, IOT and Cloud with the aim of finding the best partner for this important phase of the company. ATLAS Advanced Technologies is the second company, after PQ Design Group, with which AICUBE decides to collaborate on the DOC.D© project.

ATLAS Advanced Technologies is an Italian company specialized in the design and development of technological products. They provide solutions to create successful products. Strongly oriented to innovation and to the use of high reliability technologies for the IoT and Cloud world, for this project they field a team led by Valerio Grassi, physicist coming from the academic research world with international experience (CERN, Geneva). During his time at Unimi he has been Professor of Electronic Instrumentation for the School of Specialization in Health Physics.

The development project of the DOC.D© device foresees different phases and the joining of new industrial partners in order to achieve our goal, that of increasing the level of secondary prevention. There is in fact the possibility to make early diagnosis of diseases that if diagnosed in time can be cured or at least reduce the associated complications.

Secondary prevention can be implemented by collecting the values of specific biomarkers on a daily or weekly basis in order to have statistically significant data.

Therefore, we have patented a device that non-invasively collects a saliva sample using an "augmented" electric toothbrush. The saliva sample is then moved to a unit (base) that measures the value of the reference biomarker such as glucose for diabetes or covid-like tests in the future (once clinically tested).

AICUBE signs an agreement with Pq Design Group for industrial design.

AICUBE and Pq Design Group strategic partners for the development of DOC.D©, an innovative non-invasive device for the salivary glucose measurement in type II diabetic patients.

Milan January 22, 2021 - AICUBE innovative startup, based in Milan, strongly oriented to proactive prevention and predictive medicine through Machine Learning algorithms, has signed a contract with Pq Design Group consulting company in product design and development of innovative products.

In 2020 AICUBE reached important goals in research, device development and capital raising. It has therefore begun the path of industrialization that will lead it to the next stage of industrial prototyping. The relationship with Pq Design Group comes from an intense period of evaluation of different companies in the field of industrial design with the aim of finding the best partner for this important phase of the society.

Pq design Group is an Italian industrial design company specialized in product design and development of hi-tech products. They provide solutions to create successful products. Theirs is a consultancy that produces value, quality and innovation;

The development project of the DOC.D© device foresees different phases and the joining of new industrial partners in order to achieve our goal, that of increasing the level of secondary prevention. There is in fact the possibility to make early diagnosis of diseases that if diagnosed in time can be cured or at least reduce the associated complications.

Secondary prevention can be implemented by collecting the values of specific biomarkers on a daily or weekly basis in order to have statistically significant data.

Therefore, we have patented a device that non-invasively collects a saliva sample using an "augmented" electric toothbrush. The saliva sample is then moved to a unit (base) that measures the value of the reference biomarker such as glucose for diabetes or covid-like tests in the future (once clinically tested).



AICUBE

participates in

SMAU 2020

Booth C32


AICUBE is among the finalists

of the Gaetano Prize

Marzotto



Interview with AICUBE

of

Ernst & Young


Linkedin

YouTube

Facebook

Interview on Le Fonti TV

AICUBE at The Next Unicorns on Le Fonti with CrowdFundMe

Il Life Science in Italia tra eccellenze produttive e nuove frontiere della ricerca

Interview with AICUBE